A new version of the medicare drug catalog is coming soon, and a large number of new drugs may be coming in

"Pharmaceutical Network Industry Dynamics" Recently, the State Health Insurance Administration officially released the "2020 National Health Insurance Drug Catalog Adjustment Work Programme" and "2020 National Health Insurance Drug Catalog Adjustment Declaration Guide", which means that China's national medical insurance drug catalog adjustment work has officially started this year.
understood that this will be the fifth consecutive year of negotiations since 2016 and the second year of normal adjustments to the health care directory.
There are many bright spots in this adjustment work programme, among which it is worth mentioning that in the past, the drugs included in the list of medical insurance drugs, most of which are listed in China, new drugs abroad but not yet listed in China, are generally not included in the scope of adjustment.
But from this program, if the list of Western medicine and Chinese medicine to meet the epidemic-related respiratory disease treatment drugs, into the list of essential drugs, into the clinical urgent need for new drugs abroad list, encourage generic drug catalog or encourage research and development to declare the list of children's drugs, the second batch of national selection of drugs and other conditions, can be declared transferred.
In addition to expanding the scope of drug declaration, it is also worth noting that by December 31, 2019, the five or more provincial-level new version of the basic medical insurance drug catalog of drugs, will also be considered for inclusion in this year's drug catalog to be added to the scope of drugs.
, according to relevant sources, although the 2020 health care catalog adjustment work started relatively late, but has now developed a clear and detailed task map, timetable.
in accordance with the schedule, the drug catalog adjustment is expected to be completed by the end of the year, with the aim of landing from 2021.
, the industry believes that this year's adjustment work programme, taking into account clinical needs and schedules, new drugs or fire line into health insurance, and more than 130.
in addition, according to the Interim Measures for the Administration of Basic Medical Insurance Drugs promulgated by the State Health Insurance Administration at the end of July, the medical insurance drug catalogue will adopt a dynamic adjustment mechanism, which will be adjusted once a year in principle in the future, with the normal adjustment of the medical insurance drug catalogue, the scope of patients' drug use and access to medication will continue to increase, and the efficiency of the use of medical insurance funds will continue to improve in the future.
a comprehensive view, the introduction of this adjustment program fully reflects the new logic of health insurance billing: that is, reasonable pay, willing to pay for high-quality medical care and drugs, but not for unreasonable costs.
In this, in the future, with drug collection, medical insurance catalog adjustment, key monitoring directory, health insurance payment reform and other measures to make room for health insurance, high clinical value of innovative drugs are expected to be included one after another, while generic drugs will end the development period of high gross margin, into the "small profit and more sales" model.
this context, local enterprises need to accelerate the shift to high generic drugs, innovative drugs, in order to have more opportunities for development.